Validation of "SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade" in an independent cohort of 4,407 patients. Arbel R, Rokach L, Razi T, Tadmor T, et al. Cancer Lett 2026;643:218319.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Arbel R, Rokach L, Razi T, Tadmor T, et al. Validation of "SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade" in an independent cohort of 4,407 patients. Cancer Lett 2026;643:218319.
PMID: 41690454